I have been saying for years that for a pull incentive to actually function as an incentive, it must be large enough to motivate investors and large Pharma to get back into antibiotic R&D.
News and analysis on drug development, clinical evidence, regulatory approvals, pharmacology, and the science behind treatments — from small molecules to biologics.
